Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis

Abstract

Introduction: iGlarLixi (insulin glargine 100 U/ mL plus lixisenatide) has demonstrated glycaemic efficacy and safety in adults with inadequately controlled type 2 diabetes mellitus (T2DM). Per the European Medicines Agency's product label, iGlarLixi should be injected once a day within 1 h prior to a meal, preferably the same meal every day when the most convenient meal has been chosen. It is however unknown whether iGlarLixi administration timing affects

Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use

“…For our analysis, we pooled patient-level data from two real-life, prospective, observational studies, 11,12 part of the comprehensive European REALI programme. 13,14 The pooled studies included adults with inadequately controlled T2D, who initiated treatment with iGlar-Lixi (Suliqua ® , Sanofi, Paris, France), with or without non-insulin glucose-lowering agents, for 24 weeks. 13 For the purpose of this pooled analysis, participants were classified into two main groups based on their prior insulin use: an insulin-naïve and an insulinpretreated group.…”

“…13,14 The pooled studies included adults with inadequately controlled T2D, who initiated treatment with iGlar-Lixi (Suliqua ® , Sanofi, Paris, France), with or without non-insulin glucose-lowering agents, for 24 weeks. 13 For the purpose of this pooled analysis, participants were classified into two main groups based on their prior insulin use: an insulin-naïve and an insulinpretreated group. All participants provided written informed consent in the pooled studies, which were conducted according to the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines and approved by the appropriate ethics committees.…”

“…For our analysis, we pooled patient‐level data from two real‐life, prospective, observational studies, 11,12 part of the comprehensive European REALI programme 13,14 . The pooled studies included adults with inadequately controlled T2D, who initiated treatment with iGlarLixi (Suliqua®, Sanofi, Paris, France), with or without non‐insulin glucose‐lowering agents, for 24 weeks 13 .…”

Fixed ratio combinations GLP-1RA and basal insulin: literature review

“…При этом снижение массы тела во всех группах было сопоставимо (на 1,3–2,3 кг). Таким образом, иГларЛикси был эффективен и безопасен независимо от времени применения, однако инъекция перед завтраком способствовала более эффективному гликемическому контролю [ 34 ].…”